<DOC>
	<DOCNO>NCT00399477</DOCNO>
	<brief_summary>Patients Parkinson 's Disease ( PD ) divide 2 group study center first visit base drug take PD : - Group 1 Patients use Azilect therapy . - Group 2 Azilect combination medication like Levodopa , Mirapex , Requip .</brief_summary>
	<brief_title>A Non-Blinded Study Demonstrating Effectiveness Safety Azilect Alone Combination Therapy Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>1 . Idiopathic Parkinson 's disease . Diagnosis previously confirm presence bradykinesia least one additional cardinal sign ( i.e. , rest tremor , rigidity ) , without know suspected cause parkinsonism . 2 . Requiring therapy PD symptom control Azilect monotherapy . Azilect adjunct therapy.. 1 . Patients previously expose Azilect 2 . Patients pheochromocytoma 3 . Concomitant MAO inhibitor medication contraindicate use MAO inhibitor allow .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>